TNNI3
EstablishedCardiac troponin I is a gold-standard biomarker for diagnosing heart attacks, now used in rapid rule-in/rule-out algorithms.
Troponin I is released specifically by damaged heart muscle and is one of the two main blood tests doctors use to diagnose a heart attack. Newer, more sensitive versions of this test let doctors rule a heart attack in or out within just an hour or two in the emergency room.
TNNI3 encodes cardiac troponin I, a protein specific to heart muscle that is released into the blood when cardiac cells are damaged, making it one of the two current gold-standard biomarkers (with troponin T) for diagnosing heart attacks.
Elevated cardiac troponin I indicates myocardial injury; combined with symptoms, ECG changes, or imaging evidence of infarction, it confirms acute myocardial infarction per current universal definition criteria.
High-sensitivity troponin I assays are now explicitly preferred by ACC/AHA guidelines, using the assay-specific 99th percentile as the diagnostic threshold; there is no single universal cutoff, since values differ meaningfully between manufacturers' assays, and current guidance increasingly emphasizes sex-specific reference limits.
Current 0/1-hour or 0/2-hour high-sensitivity troponin algorithms allow rapid rule-in or rule-out of myocardial infarction in the emergency department, reducing time to diagnosis and potentially avoiding unnecessary hospital admission for patients who can be safely discharged.
No single universal cutoff exists; values are assay-specific and increasingly interpreted with sex-specific reference limits.
- AAFP. (2024). High-Sensitivity Troponin in the Diagnosis of Acute Coronary Syndrome.
- Circulation. (2022). High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC Guidelines for Acute Chest Pain.